New Century Financial Group LLC Makes New $388,000 Investment in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

New Century Financial Group LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 3,125 shares of the specialty pharmaceutical company's stock, valued at approximately $388,000.

Several other institutional investors have also made changes to their positions in the company. Focus Partners Wealth acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $551,000. Atria Investments Inc lifted its stake in shares of Jazz Pharmaceuticals by 19.5% in the 4th quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after purchasing an additional 445 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 15.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after purchasing an additional 83,807 shares during the last quarter. Rhumbline Advisers boosted its holdings in Jazz Pharmaceuticals by 1.1% in the fourth quarter. Rhumbline Advisers now owns 167,560 shares of the specialty pharmaceutical company's stock worth $20,635,000 after purchasing an additional 1,755 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after buying an additional 24,481 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares in the company, valued at $54,487,991.25. This trade represents a 0.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Seamus Mulligan bought 1,621 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, May 12th. The stock was purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the purchase, the director now directly owns 101,621 shares in the company, valued at $10,466,963. This represents a 1.62% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 3,000 shares of company stock worth $355,925. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $2.59 on Tuesday, hitting $107.05. 539,572 shares of the company were exchanged, compared to its average volume of 832,594. The company's 50 day moving average price is $107.91 and its two-hundred day moving average price is $120.35. The firm has a market capitalization of $6.48 billion, a price-to-earnings ratio of 14.27, a PEG ratio of 4.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 earnings per share. The company's revenue was down .5% on a year-over-year basis. Research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JAZZ. Piper Sandler reissued an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Morgan Stanley dropped their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Robert W. Baird lowered their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.